Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Stock Price Down 2.8% - What's Next?

Key Points

• Swedish Orphan Biovitrum's stock price fell 2.8%, trading at $28.97 with a significant increase in trading volume of 1,645% compared to its average.
• The company reported an EPS of $0.24 for the last quarter, exceeding analysts' estimates and achieving a revenue of $649.61 million.
• With a market capitalization of $10.31 billion, Swedish Orphan Biovitrum operates in the biotechnology sector, specializing in treatments for haematology, immunology, and specialty care.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) was down 2.8% during trading on Tuesday . The company traded as low as $28.94 and last traded at $28.97. Approximately 500 shares changed hands during mid-day trading, an increase of 1,645% from the average daily volume of 29 shares. The stock had previously closed at $29.79.

Swedish Orphan Biovitrum Price Performance

The company has a current ratio of 1.00, a quick ratio of 0.66 and a debt-to-equity ratio of 0.22. The business's fifty day moving average is $29.83 and its 200 day moving average is $29.53. The firm has a market capitalization of $10.31 billion, a P/E ratio of 24.34 and a beta of 0.46.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.06. The business had revenue of $649.61 million for the quarter, compared to the consensus estimate of $644.68 million. Swedish Orphan Biovitrum had a net margin of 16.05% and a return on equity of 11.67%.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.